Irisin, a newly discovered myokine, is a novel biomarker associated with physical activity in patients with chronic obstructive pulmonary disease

Respirology

Volumn 20, Issue 4, 2015, Pages 612-617

  Ijiri, Naoki ^a   Kanazawa, Hiroshi ^a   Asai, Kazuhisa ^a   Watanabe, Tetsuya ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

6 min walk distance; exercise; fibronectin type III domain containing protein 5; irisin; physical activity

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; IRISIN; UNCLASSIFIED DRUG; FIBRONECTIN; FNDC5 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SKELETAL MUSCLE;

AGED; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUSCLE FIBERS, SKELETAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84927912287     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12513     Document Type: Article

References (36)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347-365.
2. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165-1185.
3. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD-C, Jackson A, Gosker HR, Schols AMWJ, Moxham J, Polkey MI, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur. Respir. J. 2010; 36: 81-88.
4. Shrikrishna D, Patel M, Tanner RJ, Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SLF, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur. Respir. J. 2012; 40: 1115-1122.
5. Pitta F, Troosters T, Spruit MA, Vanessa S, Decramer PM, Gosselink R,. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 1171: 972-977.
6. Vaes AW, Garcia-Aymerich J, Marott JL, Benet M, Groenen MTJ, Schnohr P, Franssen FME, Vestbo J, Woulters EFM, Lange P, et al. Changes in physical activity and all-cause mortality in COPD. Eur. Respir. J. 2014; 44: 1199-1209.
7. Waschki B, Kirsten A, Holz O, Müller K-C, Meyer T, Watz H, Magnussen H,. Physical activity is the strongest predictor of all-cause mortality in patients with COPD. A prospective cohort study. Chest 2011; 140: 331-342.
8. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antõ JM,. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778.
9. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R,. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur. Respir. J. 2006; 27: 1040-1055.
10. Ward DS, Evenson KR, Vaughn A, Rodgers AB, Troiano RP,. Accelerometer use in physical activity: best practices and research recommendations. Med. Sci. Sports Exerc. 2005; 37: S582-588.
11. Nguyen HQ, Steele B, Benditt JO,. Use of accelerometers to characterize physical activity patterns with COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis. 2006; 1: 455-460.
12. Kawagoshi A, Kiyokawa N, Sugawara K, Takahashi H, Sakata S, Miura S, Sawamura S, Satake M, Shioya T,. Quantitative assessment of walking time and postural change in patients with COPD using a new triaxial accelerometer system. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 397-404.
13. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468.
14. Timmons JA, Baar K, Davidsen PK, Atherton PJ,. Is irisin a human exercise gene? Nature 2012; 488: E9-11.
15. Kelly DP,. Irisin, light my fire. Science 2012; 336: 42-43.
16. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS,. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738.
17. Polyzos SA, Kountouras J, Shields K, Mantzoros CS,. Irisin: a renaissance in metabolism? Metabolism 2013; 62: 1037-1044.
18. Moreno-Navarrete MJ, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM,. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2013; 98: E769-778.
19. Zhang H-J, Zhang X-F, Ma Z-M, Pan L-L, Chen Z, Han H-W, Han C-K, Zhuang X-J, Lu Y, Li X-J, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J. Hepatol. 2013; 59: 557-562.
20. American Thoracic Society. Standardization of spirometry. 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107-1136.
21. Robert O, Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT, Johnson D, Wanger JS, Zeballos RJ, et al. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-117.
22. Schnohr P, Scharling H, Jensen JS,. Changes in leisure-time physical activity and risk of death: an observational study of 7000 men and women. Am. J. Epidemiol. 2003; 158: 639-644.
23. Otsuka T, Kurihara N, Fujii T, Fujimoto S, Yoshikawa J,. Effect of exercise training and detraining on gas exchange kinetics in patients with chronic obstructive pulmonary disease. Clin. Physiol. 1997; 17: 287-297.
24. Watz H, Waschki B, Meyer T, Magnussen H,. Physical activity in patients with COPD. Eur. Respir. J. 2009; 33: 262-272.
25. Wen MS, Wang CY, Lin SL, Hung K-C,. Decrease in irisin in patients with chronic kidney disease. PLoS ONE 2013; 8: e64025.
26. Castillo-Quan JI,. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis. Model. Mech. 2012; 5: 293-295.
27. Greulich T, Nell C, Koepke J, Fechtel J, Franke M, Schmeck B, Haid D, Apelt S, Filipovic S, Kenn K, et al. Benefits of whole body vibration training in patients hospitalised for COPD exacerbations-a randomized clinical trial. BMC Pulm. Med. 2014; 14: 60-68.
28. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature 2012; 481: 463-468.
29. Swick AG, Orena S, O'Connor A,. Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by free fat mass. Metabolism 2013; 62: 70-73.
30. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Antõ JM,. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100-105.
31. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antõ JM,. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am. J. Respir. Crit. Care Med. 2007; 175: 458-463.
32. Leenders NY, Sherman WM, Nagaraja HN, Lawrence KC,. Evaluation of methods to assess physical activity in free-living conditions. Med. Sci. Sports Exerc. 2001; 33: 1233-1240.
33. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, ZuWallack R, Herrerias C,. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007; 131: 4s-42s.
34. Nimmo MA, Leggate M, Viana JL, King JA,. The effect of physical activity on mediators of inflammation. Diabetes Obes. Metab. 2013; 15 (Suppl. 3): 51-60.
35. Moraes C, Leal VO, Marinho SM, Barroso SG, Rocha GS, Boaventura GT, Mafra D,. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm. Metab. Res. 2013; 45: 900-904.
36. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, Garatachea N, Lucia A,. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am. J. Med. 2014; 127: 888-890.